| Today's Big NewsFeb 15, 2023 |
|
As the #1 Bioscience Manufacturing Hub in the USA, Puerto Rico is the ideal location to reshore your operations. Benefit from operational stability, world-class talent, & unmatched incentives. Learn more. 
|
|
| By Max Bayer Hours after Arrowhead Pharmaceuticals revealed that Johnson & Johnson is returning a clinical-stage NASH asset “out of the blue," CEO Chris Anzalone says that the entire $3.7 billion collaboration between the two is done. |
|
|
|
By Eric Sagonowsky Facing tens of thousands of lawsuits over cancer risks on the popular heartburn drug Zantac, GSK has argued there's "no consistent or reliable evidence" that the medicine causes any cancer. But a new report in Bloomberg Businessweek says GSK's own scientists have long known about the risks. |
By Angus Liu Biogen’s long-time chairman Stelios Papadopoulos, Ph.D., will retire from the post under company policy, potentially giving new CEO Chris Viehbacher more freedom to make bold moves to salvage the big biotech from declining revenues and a bruised reputation. |
By Annalee Armstrong Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pipeline re-prioritization underway while signaling that the formerly restrained company is ready to make some deals. |
|
GPCRs are widely recognized as premier drug targets, but over 80% of these receptors remain undrugged. This whitepaper outlines a novel solution to revolutionize GPCR drug discovery. Learn more. 
|
|
By Zoey Becker,Angus Liu,Fraiser Kansteiner,Eric Sagonowsky,Kevin Dunleavy Moderna shouldn't be at fault for any infringement of Arbutus and Genevant's patents while developing its COVID shot, The Justice Department says. The European Medicines Agency is weighing whether to make COVID-19 vaccines a yearly occurrence, much like the flu shot. Plus more. |
By Nick Paul Taylor Biogen has soured quickly on Bruton’s tyrosine kinase inhibitor orelabrutinib. Just 19 months after paying $125 million for ex-China rights in multiple sclerosis, the Big Biotech is punting the prospect back to InnoCare Pharma. |
By Andrea Park Alongside the latest round of layoffs, Titan also disclosed that it has received yet another warning notice from the Nasdaq stock exchange. |
By Fraiser Kansteiner Emergent said it’s selling its travel health business to Bavarian Nordic for an upfront payment of $270 million. Specifically, Emergent is handing over its typhoid fever vaccine Vivotif and its cholera shot Vaxchora plus the late-stage chikungunya candidate CHIKV VLP. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss which companies made the list of the top 10 pharma M&A deals of 2022 and what was at stake last year. We also talk about what last year's biggest deal means for M&A activity this year. |
|
|---|
|
|
|
Tuesday, March 14, 2023 | 2pm ET / 11am PT Join this webinarto hear industry experts across the clinical research space share their perspectives on inefficiencies in the current clinical research space, how to prioritize change, where to begin, how to measure success, and considerations when evaluating and selecting enabling technology. Register now. 
|
|
Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
Whitepaper This paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
Whitepaper Exploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
Whitepaper RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
